SuperworthIncyte profit margin INCY
Gross, operating and net profit as a share of revenue over the last twelve months, from 2010.
- Net margin, 12 months
- 27.7%
- Operating margin, 12 months
- 30.6%
- Net margin on a year earlier
- +8.7 pts
- Peer median
- 22.9%
Over the twelve months to Jun 30, 2026, Incyte kept 27.7% of its revenue as net profit, with an operating margin of 30.6% and a gross margin of 92.6%.
Five years earlier its net margin was 12.4%.
The median for 10 biotech stocks of a similar size is 22.9%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 25.0% | 29.5% | 92.8% |
| FY2024 | 0.8% | 1.4% | 92.6% |
| FY2023 | 16.2% | 16.8% | 93.1% |
| FY2022 | 10.0% | 17.1% | 93.9% |
| FY2021 | 31.8% | 19.6% | 94.9% |
| FY2020 | −11.1% | −9.9% | 95.1% |
| FY2019 | 20.7% | 18.6% | 94.7% |
| FY2018 | 5.8% | 6.9% | 95.0% |
| FY2017 | −20.4% | −15.8% | 94.8% |
| FY2016 | 9.4% | 13.1% | 94.7% |
| FY2015 | 0.9% | 6.7% | 96.4% |
| FY2014 | −9.5% | −0.9% | 99.4% |
| FY2013 | −23.4% | −4.5% | 99.8% |
| FY2012 | −14.9% | 0.4% | 99.9% |
| FY2011 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 27.7% | +8.7 pts | 30.6% | |
| Q1 FY26 | 26.7% | +26.2 pts | 30.0% | |
| Q4 FY25 | 25.0% | +24.3 pts | 29.5% | |
| Q3 FY25 | 24.7% | +23.9 pts | 30.8% | |
| Q2 FY25 | 19.0% | +16.5 pts | 25.8% | |
| Q1 FY25 | 0.5% | −19.3 pts | 4.0% | |
| Q4 FY24 | 0.8% | −15.4 pts | 1.4% | |
| Q3 FY24 | 0.8% | −11.0 pts | −1.3% | |
| Q2 FY24 | 2.5% | −7.9 pts | 0.4% | |
| Q1 FY24 | 19.8% | +10.4 pts | 18.3% | |
| Q4 FY23 | 16.2% | +6.1 pts | 16.8% | |
| Q3 FY23 | 11.8% | −14.5 pts | 13.9% |
Against its peers
Companies in Biotechnology nearest Incyte's size, closest first, today.
| Company | Profit margin |
|---|---|
| INCYIncyte | 27.7% |
| UTHRUnited Therapeutics | 41.6% |
| ALNYAlnylam Pharmaceuticals | 16.8% |
| EXELExelixis | 35.3% |
| NBIXNeurocrine Biosciences | 20.9% |
| HALOHalozyme Therapeutics | 24.9% |
| ONCBeOne Medicines | 10.7% |
| TECHBIO-TECHNE | 15.0% |
| RGENRepligen | 5.3% |
| KRYSKrystal Biotech | 54.8% |
| REGNRegeneron Pharmaceuticals | 27.9% |
| Peer median | 22.9% |
Where Incyte ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Incyte
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.